Efficacy of delayed-treatment cAC10-vcMMAE in a disseminated Karpas 299 ALCL tumor model in SCID mice. Mice were implanted with 2 × 10⁷ Karpas 299 ALCL cells into the tail vein. Groups of mice (5/group) were left untreated (*) or received 3 mg/kg of either cAC10-MMAE starting on day 9 (○) or on day 13 (•), or an irrelevant cIgG-vcMMAE starting on day 5 after tumor (▪).